The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions
Over the past two decades, significant progress has been made in the management of multiple myeloma (MM), leading to the development of novel therapeutic approaches and treatment regimens to improve patient outcomes. In patients with newly diagnosed MM (NDMM), the introduction of anti-CD38 monoclona...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2024.21.159 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841525462742859776 |
|---|---|
| author | Yuxin Liu Clifton Mo Monique Hartley-Brown Shonali Midha Adam S. Sperling Giada Bianchi Omar Nadeem Betsy O’Donnell Jacob Laubach Paul G. Richardson |
| author_facet | Yuxin Liu Clifton Mo Monique Hartley-Brown Shonali Midha Adam S. Sperling Giada Bianchi Omar Nadeem Betsy O’Donnell Jacob Laubach Paul G. Richardson |
| author_sort | Yuxin Liu |
| collection | DOAJ |
| description | Over the past two decades, significant progress has been made in the management of multiple myeloma (MM), leading to the development of novel therapeutic approaches and treatment regimens to improve patient outcomes. In patients with newly diagnosed MM (NDMM), the introduction of anti-CD38 monoclonal antibodies daratumumab and isatuximab has significantly extended patient survival while maintaining a manageable toxicity profile and building upon the success of highly active triplet combinations incorporating immunomodulatory drugs, proteasome inhibitors and dexamethasone. Treatment strategies based on the assessment of minimal residual disease (MRD) negativity, a strong prognostic marker for durable responses, allow for improved decision making in MM management. Active ongoing research aims to assess how novel therapies may improve outcomes in both frontline and maintenance settings. This review article discusses recent advances in NDMM therapy, with a focus on quadruplet versus triplet anti-CD38 mAb-based regimens and MRD-driven approaches, as well as emerging alternative therapeutic strategies, including transplant-sparing approaches to meaningfully improve patient outcome. Ongoing trials are also outlined, including the data presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the 2024 European Hematology Association (EHA) Congress and the 21st International Myeloma Society (IMS) Annual Meeting 2024.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Dr Adrian Schmidt, Stadtspital Zurich Triemli, Zurich, Switzerland
Dr Carmen de Ramon Ortiz, Geneva University Hospitals, Geneva, Switzerland
One anonymous peer reviewer
Received on August 10, 2024; accepted after peer review on October 20, 2024; published online on October 30, 2024. |
| format | Article |
| id | doaj-art-787fc8e190764ab687af8cf0e9b9a3b8 |
| institution | Kabale University |
| issn | 2673-2106 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-787fc8e190764ab687af8cf0e9b9a3b82025-01-17T12:15:33ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-21062024-10-01213The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future DirectionsYuxin LiuClifton MoMonique Hartley-BrownShonali MidhaAdam S. SperlingGiada BianchiOmar NadeemBetsy O’DonnellJacob LaubachPaul G. RichardsonOver the past two decades, significant progress has been made in the management of multiple myeloma (MM), leading to the development of novel therapeutic approaches and treatment regimens to improve patient outcomes. In patients with newly diagnosed MM (NDMM), the introduction of anti-CD38 monoclonal antibodies daratumumab and isatuximab has significantly extended patient survival while maintaining a manageable toxicity profile and building upon the success of highly active triplet combinations incorporating immunomodulatory drugs, proteasome inhibitors and dexamethasone. Treatment strategies based on the assessment of minimal residual disease (MRD) negativity, a strong prognostic marker for durable responses, allow for improved decision making in MM management. Active ongoing research aims to assess how novel therapies may improve outcomes in both frontline and maintenance settings. This review article discusses recent advances in NDMM therapy, with a focus on quadruplet versus triplet anti-CD38 mAb-based regimens and MRD-driven approaches, as well as emerging alternative therapeutic strategies, including transplant-sparing approaches to meaningfully improve patient outcome. Ongoing trials are also outlined, including the data presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the 2024 European Hematology Association (EHA) Congress and the 21st International Myeloma Society (IMS) Annual Meeting 2024. PEER REVIEWED ARTICLE **Peer reviewers:** Dr Adrian Schmidt, Stadtspital Zurich Triemli, Zurich, Switzerland Dr Carmen de Ramon Ortiz, Geneva University Hospitals, Geneva, Switzerland One anonymous peer reviewer Received on August 10, 2024; accepted after peer review on October 20, 2024; published online on October 30, 2024.https://doi.org/10.36000/HBT.OH.2024.21.159 |
| spellingShingle | Yuxin Liu Clifton Mo Monique Hartley-Brown Shonali Midha Adam S. Sperling Giada Bianchi Omar Nadeem Betsy O’Donnell Jacob Laubach Paul G. Richardson The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions healthbook TIMES. Oncology Hematology |
| title | The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions |
| title_full | The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions |
| title_fullStr | The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions |
| title_full_unstemmed | The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions |
| title_short | The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions |
| title_sort | rapidly evolving treatment landscape in newly diagnosed multiple myeloma current status and future directions |
| url | https://doi.org/10.36000/HBT.OH.2024.21.159 |
| work_keys_str_mv | AT yuxinliu therapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT cliftonmo therapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT moniquehartleybrown therapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT shonalimidha therapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT adamssperling therapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT giadabianchi therapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT omarnadeem therapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT betsyodonnell therapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT jacoblaubach therapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT paulgrichardson therapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT yuxinliu rapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT cliftonmo rapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT moniquehartleybrown rapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT shonalimidha rapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT adamssperling rapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT giadabianchi rapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT omarnadeem rapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT betsyodonnell rapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT jacoblaubach rapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections AT paulgrichardson rapidlyevolvingtreatmentlandscapeinnewlydiagnosedmultiplemyelomacurrentstatusandfuturedirections |